biostudies-literatureUnknownBogdanski AM<h4>Objectives</h4>New methods are needed to detect pancreatic ductal adenocarcinoma (PDAC) earlier to improve outcomes. We previously reported that a panel of protein N-glycosylation traits (NGTs) discriminated PDAC from healthy-controls with an area under the curve (AUC) of 0.81-0.88. However, it remained unclear whether this panel accurately differentiates PDAC from other benign pancreatic disorders. Our study aims to evaluate the performance of the NGT panel in combination with CA19-9, in a diverse cohort, including PDAC cases, healthy-controls and controls with benign pancreatic disorders.<h4>Methods</h4>Protein N-glycosylation profiles were determined in plasma samples using an in-house developed mass spectrometry assay. CA19-9 levels were measured using routine immunoassay test. ResPancreashttps://www.ebi.ac.uk/biostudies/studies/S-EPMC12419019biostudies-literatureProtein N-Glycosylation Traits Combined with CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases.PMC12419019Ballieux BEPBCobbaert CMClift KEMesker WEKlatte DCFWallace MBvan der Burgt YEMvan Leerdam MEvan Hooft JEBogdanski AMWuhrer MBi YfalseProtein N-Glycosylation Traits Combined with CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases.<h4>Objectives</h4>New methods are needed to detect pancreatic ductal adenocarcinoma (PDAC) earlier to improve outcomes. We previously reported that a panel of protein N-glycosylation traits (NGTs) discriminated PDAC from healthy-controls with an area under the curve (AUC) of 0.81-0.88. However, it remained unclear whether this panel accurately differentiates PDAC from other benign pancreatic disorders. Our study aims to evaluate the performance of the NGT panel in combination with CA19-9, in a diverse cohort, including PDAC cases, healthy-controls and controls with benign pancreatic disorders.<h4>Methods</h4>Protein N-glycosylation profiles were determined in plasma samples using an in-house developed mass spectrometry assay. CA19-9 levels were measured using routine immunoassay test. Res2025-01-01T00:00:00Z2025 May2026-06-02T01:01:54.347Z2026-05-24T03:07:36.603ZS-EPMC124190194040328710.1097/MPA.0000000000002517